Clinical trials
Parkinson Disease trials in Hungary
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 5 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 5 |
| Boehringer Ingelheim | 5 |
| Somogy Megyei Kaposi Mór Teaching Hospital | 5 |
| GlaxoSmithKline | 3 |
| Novartis Pharmaceuticals | 3 |
| UCB Pharma | 3 |
| Theravance Biopharma | 2 |
| Acorda Therapeutics | 1 |
| Annovis Bio Inc. | 1 |
| Boston Scientific Corporation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Parkinson Disease | 43 |
| Movement Disorders | 8 |
| Parkinsonian Disorders | 8 |
| Dyskinesias | 5 |
| Brain Diseases | 3 |
| Central Nervous System Diseases | 3 |
| Nervous System Diseases | 3 |
| Neurodegenerative Diseases | 3 |
| Disease | 2 |
| Dizziness | 2 |
Trials
Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.